AzTrials
AzTrials

Non Small Cell Lung CancerPhase 3TroFuse-019NCT06312137

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

A Phase 3 study testing Sacituzumab tirumotecan, Pembrolizumab and Cisplatin in people with Non Small Cell Lung Cancer, run by Merck Sharp & Dohme LLC at 270 sites in 31 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Non Small Cell Lung Cancer
What is being tested?
Sacituzumab tirumotecan, Pembrolizumab and Cisplatin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
780 participants
Where
270 sitesin 31 countries
Study dates
3 Apr 2024to 23 Oct 2034
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2]) per AJCC eighth edition guidelines
  • Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy
  • Is able to undergo surgery based on opinion of investigator after consultation with surgeon
  • Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy
  • Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.
  • Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period
Show all 11Show fewer
  • Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible
  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention

Who cannot join

  • Has one of the following tumor locations/types:
  • NSCLC involving the superior sulcus
  • Large cell neuro-endocrine cancer (LCNEC)
  • Sarcomatoid tumor
  • Diagnosis of SCLC or, for mixed tumors, presence of small cell elements
  • Has Grade ≥2 peripheral neuropathy
Show all 24Show fewer
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Has received prior neoadjuvant therapy for their current NSCLC diagnosis
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
  • Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years
  • Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis, has current ILD/pneumonitis, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
  • Has an active infection requiring systemic therapy
  • Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection
  • Has a history of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or have ongoing surgical complications
  • Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy

Trial locations and contacts

270 sites in 31 countries. Contact the study team or a site near you to ask about taking part.

Toll Free Number contact

1-888-577-8839

Trialsites@msd.com

270 sites in 31 countries

United States51 sites, 45 recruiting

  • Piedmont Atlanta Hospital ( Site 4000)

    Atlanta, Georgia, 30318

    Study Coordinator, 404-425-1777

    Recruiting

  • Emory University School of Medicine-Phase I ( Site 0056)

    Atlanta, Georgia, 30322

    Study Coordinator, 404-778-1900

    Recruiting

  • Northside Hospital ( Site 0055)

    Atlanta, Georgia, 30342

    Study Coordinator, 404-851-8000

    Recruiting

  • LSU Health Baton Rouge North Clinic ( Site 4003)

    Baton Rouge, Louisiana, 70805

    Study Coordinator, 225-765-7956

    Recruiting

  • Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080)

    Baton Rouge, Louisiana, 70808

    Study Coordinator, 225-765-7956

    Recruiting

  • Beverly Hills Cancer Center ( Site 0070)

    Beverly Hills, California, 90211

    Study Coordinator, 310-432-8933

    Recruiting

  • Saint Joseph's Candler Health System ( Site 4010)

    Bluffton, South Carolina, 29910

    Study Coordinator, 912-819-5704

    Recruiting

  • Medical University of South Carolina-Hollings Cancer Center ( Site 0045)

    Charleston, South Carolina, 29425

    Study Coordinator, 843-792-4271

    Recruiting

  • Centricity Research Columbus Cancer Center ( Site 0005)

    Columbus, Georgia, 31904

    Completed

  • Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061)

    Edgewood, Kentucky, 41017

    Study Coordinator, 859-301-4736

    Recruiting

  • Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0017)

    Elmhurst, Illinois, 60126

    Completed

  • North Shore University Health System ( Site 4014)

    Evanston, Illinois, 60201

    Study Coordinator, 847-540-2112

    Recruiting

  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057)

    Fargo, North Dakota, 58102

    Study Coordinator, 701-234-6161

    Recruiting

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0089)

    Fort Wayne, Indiana, 46845

    Study Coordinator, 260-266-6626

    Recruiting

  • Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059)

    Hershey, Pennsylvania, 17033

    Study Coordinator, 717-531-0003

    Recruiting

  • Millennium Research & Clinical Development ( Site 0039)

    Houston, Texas, 77090

    Completed

  • Cayuga Medical Center ( Site 0086)

    Ithaca, New York, 14850

    Study Coordinator, 607-277-4341

    Recruiting

  • Mayo Clinic in Florida ( Site 0014)

    Jacksonville, Florida, 32224

    Study Coordinator, 904-953-3570

    Recruiting

  • University of Tennessee Medical Center Knoxville ( Site 0082)

    Knoxville, Tennessee, 37920

    Study Coordinator, 865-305-9000

    Recruiting

  • Indiana University Health Arnett Cancer Center ( Site 0076)

    Lafayette, Indiana, 47904

    Study Coordinator, 765-838-6885

    Recruiting

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068)

    Lancaster, Pennsylvania, 17601

    Study Coordinator, 717-544-0511

    Recruiting

  • Accellacare of Duly ( Site 4005)

    Lisle, Illinois, 60532

    Study Coordinator, 630-545-7760

    Recruiting

  • UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

    Little Rock, Arkansas, 72205

    Study Coordinator, 601-278-6499

    Recruiting

  • The Angeles Clinic and Research Institute ( Site 0040)

    Los Angeles, California, 90025

    Completed

  • The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate ( Site 0079)

    Los Angeles, California, 90025

    Completed

  • UCLA Clinical & Translational Research Center (CTRC) ( Site 0033)

    Los Angeles, California, 90095

    Study Coordinator, 424-325-9070

    Recruiting

  • Mount Sinai Cancer Center ( Site 0038)

    Miami Beach, Florida, 33140

    Study Coordinator, 305-674-2625

    Recruiting

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027)

    Minneapolis, Minnesota, 55407

    Study Coordinator, 888-425-5462

    Recruiting

  • Atlantic Health Morristown Medical Center ( Site 0077)

    Morristown, New Jersey, 07960

    Study Coordinator, 973-971-7000

    Recruiting

  • Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0078)

    Naperville, Illinois, 60540

    Completed

  • Southeastern Regional Medical Center ( Site 0065)

    Newnan, Georgia, 30265

    Study Coordinator, 770-400-6000

    Recruiting

  • Hoag Memorial Hospital Presbyterian ( Site 0096)

    Newport Beach, California, 92663

    Study Coordinator, 949-764-4060

    Recruiting

  • Hightower Clinical, LLC ( Site 0084)

    Oklahoma City, Oklahoma, 73102

    Study Coordinator, 405-479-8331

    Recruiting

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002)

    Orange, California, 92868

    Study Coordinator, 714-734-6220

    Recruiting

  • Mid Florida Hematology and Oncology Center ( Site 0018)

    Orange City, Florida, 32763

    Study Coordinator, 386-960-7070

    Recruiting

  • Oregon Health and Science University ( Site 0052)

    Portland, Oregon, 97239

    Study Coordinator, 503-494-0283

    Recruiting

  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037)

    Reno, Nevada, 89502

    Study Coordinator, 775-982-5050

    Recruiting

  • Mayo Clinic - Rochester ( Site 0073)

    Rochester, Minnesota, 55905

    Study Coordinator, 904-953-1050

    Recruiting

  • Huntsman Cancer Institute ( Site 0042)

    Salt Lake City, Utah, 84112-5500

    Study Coordinator, 801-587-7000

    Recruiting

  • San Francisco Oncology Associates ( Site 0066)

    San Francisco, California, 94115

    Study Coordinator, 415-600-1102

    Recruiting

  • Lewis Cancer and Research Pavilion ( Site 0063)

    Savannah, Georgia, 31405

    Study Coordinator, 912-819-5704

    Recruiting

  • Sanford Cancer Center ( Site 0053)

    Sioux Falls, South Dakota, 57104

    Study Coordinator, 605-328-8800

    Recruiting

  • Avera Cancer Institute- Research ( Site 0090)

    Sioux Falls, South Dakota, 57105

    Study Coordinator, 605-322-3295

    Recruiting

  • Highlands Oncology Group-Research Department ( Site 0062)

    Springdale, Arkansas, 72762

    Study Coordinator, 479-334-2562

    Recruiting

  • Mercy South - David M Sindelar Cancer Center ( Site 0098)

    St Louis, Missouri, 63128

    Study Coordinator, 314-525-4928

    Recruiting

  • Mercy Research - David C. Pratt Cancer Center ( Site 0006)

    St Louis, Missouri, 63141

    Study Coordinator, 314-251-4400

    Recruiting

  • Stamford Hospital ( Site 0083)

    Stamford, Connecticut, 06902

    Study Coordinator, 203-358-8879

    Recruiting

  • University Hospital at Stony Brook ( Site 0054)

    Stony Brook, New York, 11794

    Study Coordinator, 631-372-7212

    Recruiting

  • Archbold Cancer Center ( Site 0071)

    Thomasville, Georgia, 31792

    Study Coordinator, 229-584-5417

    Recruiting

  • New England Cancer Specialists ( Site 0095)

    Westbrook, Maine, 04092

    Study Coordinator, 207-303-3300

    Recruiting

  • White Plains Hospital ( Site 0091)

    White Plains, New York, 10601

    Study Coordinator, 914-681-0600

    Recruiting

Other trials in United States

China27 sites, 26 recruiting

  • Beijing Cancer hospital-Thoracic Surgery department I ( Site 1301)

    Beijing, Beijing Municipality, 100010

    Study Coordinator, 86-10-88121122

    Recruiting

  • Beijing Peking Union Medical College Hospital-Thoracic surgery department ( Site 1302)

    Beijing, Beijing Municipality, 100730

    Study Coordinator, 86-10-69151188

    Recruiting

  • Peking University People's Hospital ( Site 1300)

    Beijing, Beijing Municipality, 101109

    Study Coordinator, 01088326666

    Recruiting

  • The First Hospital of Jilin University ( Site 1324)

    Changchun, Jilin, 130031

    Study Coordinator, +86-431-81875309

    Recruiting

  • Xiangya Hospital Central South University-Thoracic surgery ( Site 1311)

    Changsha, Hunan, 410008

    Study Coordinator, 0731-89753003

    Recruiting

  • Hunan Cancer Hospital ( Site 1312)

    Changsha, Hunan, 410013

    Study Coordinator, 0731-89762112

    Recruiting

  • Sichuan Cancer hospital. ( Site 1327)

    Chengdu, Sichuan, 610042

    Study Coordinator, 028-85420156

    Recruiting

  • Fujian Cancer Hospital-oncology department ( Site 1314)

    Fuzhou, Fujian, 350014

    Study Coordinator, 0591-83660063

    Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University-thoracic surgery department ( Site 1320)

    Guangzhou, Guangdong, 510120

    Study Coordinator, +86 13660202355

    Recruiting

  • Southern Medical University Nanfang Hospital-Thoracic surgery department ( Site 1313)

    Guangzhou, Guangdong, 510515

    Study Coordinator, 020-61641821

    Recruiting

  • The first Affiliated Hospital, Zhejiang University School of-Thoracic Cardiovascular Surgery Ward ( Site 1303)

    Hangzhou, Zhejiang, 310003

    Study Coordinator, 0571-87236114

    Recruiting

  • Zhejiang Cancer Hospital ( Site 1309)

    Hangzhou, Zhejiang, 310022

    Study Coordinator, 0571-88128276

    Recruiting

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 1328)

    Hangzhou, Zhejiang, 31009

    Study Coordinator, 0571-86006992

    Recruiting

  • Shandong Cancer Hospital ( Site 1321)

    Jinan, Shandong, 250117

    Study Coordinator, +86-531-67626232

    Recruiting

  • Yunnan Province Cancer Hospital ( Site 1315)

    Kunming, Yunnan, 650107

    Study Coordinator, 087168178106

    Recruiting

  • Taizhou Hospital of Zhejiang Province ( Site 1329)

    Linhai, Zhejiang, 317000

    Study Coordinator, 0576-85199810

    Recruiting

  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 1330)

    Nanchang, Jiangxi, 330209

    Study Coordinator, 0791-88695051

    Recruiting

  • Nanjing First Hospital ( Site 1310)

    Nanjing, Jiangsu, 210012

    Study Coordinator, 025-52271064

    Recruiting

  • The Second People's Hospital of Neijiang ( Site 1322)

    Neijiang, Sichuan, 641000

    Completed

  • Ningbo No. 2 Hospital ( Site 1305)

    Ningbo, Zhejiang, 315010

    Study Coordinator, 057483870375

    Recruiting

  • Zhongshan Hospital Fudan University ( Site 1325)

    Shanghai, Shanghai Municipality, 200032

    Study Coordinator, 02131587861

    Recruiting

  • Shanghai Pulmonary Hospital-Thoracic Surgery department ( Site 1304)

    Shanghai, Shanghai Municipality, 200433

    Study Coordinator, 021-65115006

    Recruiting

  • The First Affiliated Hospital of Soochow University-Thoracic Surgery Department ( Site 1318)

    Suzhou, Jiangsu, 215006

    Study Coordinator, 0512-67780040

    Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology-Thoracic Surgery ( Site 1306)

    Wuhan, Hubei, 430022

    Study Coordinator, 027-85351615

    Recruiting

  • Hubei Cancer Hospital ( Site 1308)

    Wuhan, Hubei, 430079

    Study Coordinator, 027-87670445

    Recruiting

  • The Second Affiliated Hospital of Air Force Medical University ( Site 1332)

    Xi'an, Shaanxi, 710038

    Study Coordinator, 02984756100

    Recruiting

  • Henan Cancer Hospital-henan cancer hospital ( Site 1316)

    Zhengzhou, Henan, 450000

    Study Coordinator, 0371-65588178

    Recruiting

Other trials in China

Japan20 sites, 20 recruiting

  • Juntendo University Hospital ( Site 1204)

    Bunkyo-ku, Tokyo, 113-8431

    Study Coordinator, +81-3-3813-3111

    Recruiting

  • National Hospital Organization Kyushu Cancer Center ( Site 1218)

    Fukuoka, 811-1395

    Study Coordinator, +81-92-541-3231

    Recruiting

  • Fukushima Medical University Hospital ( Site 1200)

    Fukushima, 960-1295

    Study Coordinator, +81-24-547-1111

    Recruiting

  • Kansai Medical University Hospital ( Site 1211)

    Hirakata, Osaka, 573-1191

    Study Coordinator, +81-72-804-0101

    Recruiting

  • Hiroshima University Hospital ( Site 1215)

    Hiroshima, 734-8551

    Study Coordinator, +81-82-257-5555

    Recruiting

  • National Cancer Center Hospital East ( Site 1202)

    Kashiwa, Chiba, 277-8577

    Study Coordinator, +81-4-7133-1111

    Recruiting

  • St. Marianna University Hospital ( Site 1207)

    Kawasaki, Kanagawa, 216-8511

    Study Coordinator, +81-44-977-8111

    Recruiting

  • Saitama Prefectural Cancer Center ( Site 1201)

    Kitaadachi-gun, Saitama, 3620806

    Study Coordinator, +81-48-722-1111

    Recruiting

  • Hospital of the University of Occupational and Environmental Health, Japan ( Site 1217)

    Kitakyushu, Fukuoka, 807-8556

    Study Coordinator, +81-93-603-1611

    Recruiting

  • Kobe City Medical Center General Hospital ( Site 1213)

    Kobe, Hyōgo, 650-0047

    Study Coordinator, +81-78-302-4321

    Recruiting

  • National Hospital Organization Shikoku Cancer Center ( Site 1216)

    Matsuyama, Ehime, 791-0280

    Study Coordinator, +81-89-999-1111

    Recruiting

  • Nagasaki University Hospital ( Site 1220)

    Nagasaki, 852-8501

    Study Coordinator, +81-95-819-7200

    Recruiting

  • Niigata Cancer Center Hospital ( Site 1208)

    Niigata, 951-8566

    Study Coordinator, +81-25-266-5111

    Recruiting

  • Okayama University Hospital ( Site 1214)

    Okayama, 700-8558

    Study Coordinator, +81-86-235-7991

    Recruiting

  • Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 1210)

    Osaka, 541-8567

    Study Coordinator, +81-6-6945-1181

    Recruiting

  • Kindai University Hospital ( Site 1212)

    Sakai, Osaka, 590-0197

    Study Coordinator, +81-72-366-0221

    Recruiting

  • Tokyo Medical University Hospital ( Site 1203)

    Shinjuku, Tokyo, 160-0023

    Study Coordinator, +81-3-3342-6111

    Recruiting

  • Nippon Medical School Hospital ( Site 1205)

    Tokyo, 113-8603

    Study Coordinator, +81-3-3822-2131

    Recruiting

  • Yamagata University Hospital ( Site 1219)

    Yamagata, 990-9585

    Study Coordinator, +81-23-633-1122

    Recruiting

  • Kanagawa Cancer Center ( Site 1206)

    Yokohama, Kanagawa, 241-8515

    Study Coordinator, +81-45-520-2222

    Recruiting

Other trials in Japan

Italy14 sites, 14 recruiting

  • Humanitas Gavazzeni-ONCOLOGY ( Site 2310)

    Bergamo, 24125

    Study Coordinator, +390354204106

    Recruiting

  • Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 2307)

    Florence, Tuscany, 50134

    Study Coordinator, +390557947298

    Recruiting

  • Ospedale San Martino ( Site 2313)

    Genova, 16132

    Study Coordinator, +390105558918

    Recruiting

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 2302)

    Meldola, Emilia-Romagna, 47014

    Study Coordinator, +393487469100

    Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 2300)

    Milan, Lombardy, 20133

    Study Coordinator, +390223903829

    Recruiting

  • San Paolo - ASST SANTI PAOLO E CARLO ( Site 2314)

    Milan, Lombardy, 20142

    Study Coordinator, +390240222119

    Recruiting

  • Ospedale San Raffaele-Oncologia Medica ( Site 2311)

    Milan, 20132

    Study Coordinator, +390226434856

    Recruiting

  • Humanitas Istituto Clinico Catanese ( Site 2315)

    Misterbianco, Catania, 95045

    Study Coordinator, +3909573390167

    Recruiting

  • Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2301)

    Monza, Lombardy, 20900

    Study Coordinator, +390392339285

    Recruiting

  • Azienda Ospedaliero Universitaria di Parma ( Site 2312)

    Parma, 43126

    Study Coordinator, +39521702660

    Recruiting

  • Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 2303)

    Pavia, 27100

    Study Coordinator, +390382503938

    Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 2306)

    Roma, 00168

    Study Coordinator, +390630156318

    Recruiting

  • Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 2309)

    Rome, Roma, 00144

    Study Coordinator, 0652665698

    Recruiting

  • APSS- Presidio Ospedaliero S. Chiara ( Site 2304)

    Trento, 38122

    Study Coordinator, +390461902478

    Recruiting

Other trials in Italy

Germany12 sites, 12 recruiting

  • Zentralklinik Bad Berka-Klinik für Hämatologie und Onkologie ( Site 1902)

    Bad Berka, Thuringia, 99437

    Study Coordinator, +493645851501

    Recruiting

  • Evangelische Lungenklinik Berlin-Pneumologie ( Site 1904)

    Berlin, 13125

    Study Coordinator, +4930948020

    Recruiting

  • Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1903)

    Berlin, 13353

    Study Coordinator, +4930450553412

    Recruiting

  • Vivantes Hospital Spandau-Klinik für Innere Medizin, Hämatologie, Onkologie und Gastroenterologie- ( Site 1912)

    Berlin, 13585

    Study Coordinator, 4930130132629

    Recruiting

  • Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1916)

    Berlin, 14165

    Study Coordinator, +493081021506

    Recruiting

  • Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1914)

    Esslingen am Neckar, Baden-Wurttemberg, 73730

    Study Coordinator, 71131032402

    Recruiting

  • SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 1900)

    Gera, Thuringia, 07548

    Study Coordinator, +493658282151

    Recruiting

  • Krankenhaus Martha-Maria Halle-Dölau-Klinik für Innere Medizin II ( Site 1908)

    Halle, Saxony-Anhalt, 06120

    Study Coordinator, +493455591434

    Recruiting

  • Lungenklinik Hemer ( Site 1905)

    Hemer, North Rhine-Westphalia, 58675

    Study Coordinator, 02372 9080

    Recruiting

  • Katholisches Klinikum Koblenz ( Site 1911)

    Koblenz, Rhineland-Palatinate, 56073

    Study Coordinator, 00492614964095

    Recruiting

  • Universitätsklinikum Leipzig ( Site 1915)

    Leipzig, Saxony, 04103

    Study Coordinator, 00493419712600

    Recruiting

  • Universitaetsklinikum Regensburg ( Site 1907)

    Regensburg, Bavaria, 93053

    Study Coordinator, +499419447285

    Recruiting

Other trials in Germany

Romania11 sites, 9 recruiting

  • SC ONCO CARD SRL ( Site 2808)

    Brasov, 500052

    Study Coordinator, +40268960

    Recruiting

  • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L.. ( Site 2803)

    Bucharest, Bucharest, 013823

    Study Coordinator, +40319393

    Recruiting

  • Institutul Oncologic Bucuresti Prof.Dr. Alex. Trestioreanu ( Site 2809)

    Bucharest, Bucharest, 022328

    Study Coordinator, +40212271000

    Recruiting

  • SC MNT HEALTHCARE EUROPE SRL ( Site 2811)

    Bucharest, 013975

    Study Coordinator, +40 21 9230

    Recruiting

  • Delta Health Care SRL ( Site 2810)

    Bucharest, 014142

    Study Coordinator, +40 21 9977

    Recruiting

  • Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu ( Site 2804)

    Bucharest, 077015

    Study Coordinator, +40213161600

    Recruiting

  • Cardiomed SRL Cluj-Napoca-Medical Oncology ( Site 2801)

    Cluj-Napoca, Cluj, 400015

    Completed

  • Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2805)

    Craiova, Dolj, 200542

    Completed

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2802)

    Florești, Cluj, 407280

    Study Coordinator, +40219368

    Recruiting

  • Institutul Regional de Oncologie ( Site 2807)

    Iași, 700483

    Study Coordinator, +40374.278.811

    Recruiting

  • Spitalul Clinic Municipal De Urgenta Timisoara ( Site 2806)

    Timișoara, Timiș County, 300595

    Study Coordinator, +40256200048

    Recruiting

Other trials in Romania

France10 sites, 10 recruiting

  • CHRU de Brest ( Site 1804)

    Brest, Finistere, 29609

    Study Coordinator, +33298223298

    Recruiting

  • Hospices Civils de Lyon - Hopital Louis Pradel ( Site 1809)

    Bron, Rhone, 69677

    Study Coordinator, +33427855594

    Recruiting

  • Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810)

    Clermont-Ferrand, Puy-de-Dome, 63003

    Study Coordinator, +33473278080

    Recruiting

  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1805)

    Limoges, Haute-Vienne, 87042

    Study Coordinator, 33555056892

    Recruiting

  • Hôpital Tenon ( Site 1802)

    Paris, 75020

    Study Coordinator, 33156016531

    Recruiting

  • Groupe hospitalier Paris saint Joseph. ( Site 1807)

    Paris, Île-de-France Region, 75014

    Study Coordinator, +33144123159

    Recruiting

  • CHU Charles Nicolle ( Site 1803)

    Rouen, Haute-Normandie, 76000

    Study Coordinator, +33232888079

    Recruiting

  • HIA Sainte Anne ( Site 1800)

    Toulon, Var, 83800 Cede

    Study Coordinator, 0033483162937

    Recruiting

  • CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1801)

    Toulouse, Haute-Garonne, 31400

    Study Coordinator, +33567771859

    Recruiting

  • Clinique Teissier Groupe ( Site 1811)

    Valenciennes, Nord, 59304

    Study Coordinator, +33327142434

    Recruiting

Other trials in France

Poland10 sites, 8 recruiting

  • Bialostockie Centrum Onkologii ( Site 2604)

    Bialystok, Podlaskie Voivodeship, 15-027

    Study Coordinator, +48856646732

    Recruiting

  • Uniwersytecki Szpital Kliniczny w Białymstoku ( Site 2612)

    Bialystok, Podlaskie Voivodeship, 15-540

    Study Coordinator, 858316522

    Recruiting

  • Uniwersyteckie Centrum Kliniczne ( Site 2610)

    Gdansk, Pomeranian Voivodeship, 80-214

    Active, not recruiting

  • Krakowski Szpital Specjalistyczny im. Jana Pawła II ( Site 2614)

    Krakow, Lesser Poland Voivodeship, 31-202

    Study Coordinator, +48126142000

    Recruiting

  • Uniwersytecki Szpital Kliniczny nr 4 w Lublinie ( Site 2611)

    Lublin, Lublin Voivodeship, 20-090

    Study Coordinator, +48 602405127

    Recruiting

  • Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemioterapii ( Site 2606)

    Olsztyn, Warmian-Masurian Voivodeship, 10-357

    Study Coordinator, +48895322935

    Recruiting

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 2602)

    Poznan, Greater Poland Voivodeship, 60-569

    Completed

  • Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 2613)

    Prabuty, Pomeranian Voivodeship, 82-550

    Study Coordinator, +48 552624328

    Recruiting

  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2601)

    Przemyśl, Podkarpackie Voivodeship, 37-700

    Study Coordinator, +48166775000

    Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2600)

    Warsaw, Masovian Voivodeship, 02-781

    Study Coordinator, +48225463066

    Recruiting

Other trials in Poland

Greece8 sites, 8 recruiting

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 2000)

    Athens, Attica, 115 27

    Study Coordinator, +302107700220

    Recruiting

  • Athens Medical Center ( Site 2005)

    Athens, Attica, 151 25

    Study Coordinator, +302106157392

    Recruiting

  • University General Hospital of Heraklion-Internal Medicine-Oncology ( Site 2001)

    Heraklion, Irakleio, 715 00

    Study Coordinator, 0030 2810392438

    Recruiting

  • University General Hospital of Larissa-Oncology Clinic ( Site 2004)

    Larissa, Thessaly, 411 10

    Study Coordinator, +302413502124

    Recruiting

  • Athens Medical Center ( Site 2003)

    Marousi, Attica, 151 25

    Study Coordinator, 0030 2107464642

    Recruiting

  • UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 2006)

    Pátrai, Achaia, 26504

    Study Coordinator, +302610999791

    Recruiting

  • Metaxa Cancer Hospital of Piraeus ( Site 2002)

    Piraeus, Attica, 185 37

    Study Coordinator, +302132079225

    Recruiting

  • European Interbalkan Medical Center ( Site 2007)

    Thessaloniki, 570 01

    Study Coordinator, 0030 2310400213

    Recruiting

Other trials in Greece

Netherlands8 sites, 8 recruiting

  • Meander Medisch Centrum-Researchbureau Longgeneeskunde ( Site 3458)

    Amersfoort, Utrecht, 3813TZ

    Study Coordinator, +31338507843

    Recruiting

  • Amphia Ziekenhuis, locatie Breda Molengracht-long oncologie ( Site 3453)

    Breda, North Brabant, 4818 CK

    Study Coordinator, +0765955349

    Recruiting

  • University Medical Center Groningen ( Site 3459)

    Groningen, 9713 GZ

    Study Coordinator, 0503616161

    Recruiting

  • Martini Ziekenhuis ( Site 3460)

    Groningen, 9728 NT

    Study Coordinator, 0505246311

    Recruiting

  • Leids Universitair Medisch Centrum-Longziekten ( Site 3451)

    Leiden, South Holland, 2333 ZG

    Study Coordinator, 0715262950

    Recruiting

  • Erasmus Medisch Centrum ( Site 3452)

    Rotterdam, South Holland, 3015 GD

    Study Coordinator, +0107030323

    Recruiting

  • Sint Antonius Ziekenhuis ( Site 3455)

    Utrecht, 3543 AZ

    Study Coordinator, +0883201411

    Recruiting

  • Isala, locatie Zwolle-Poli Longziekten ( Site 3454)

    Zwolle, Overijssel, 8025 BK

    Study Coordinator, +0031655804447

    Recruiting

Other trials in Netherlands

Turkey (Türkiye)8 sites, 8 recruiting

  • Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3106)

    Adana, 01140

    Study Coordinator, +903223444444

    Recruiting

  • Gulhane Egitim Arastirma Hastanesi-Onkoloji ( Site 3104)

    Ankara, 06010

    Study Coordinator, 00903123042000

    Recruiting

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 3101)

    Ankara, 06230

    Study Coordinator, +90 (312) 305 50 00

    Recruiting

  • Memorial Ankara Hastanesi-Medical Oncology ( Site 3110)

    Ankara, 06520

    Study Coordinator, 903122536666

    Recruiting

  • Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3103)

    Ankara, 06800

    Study Coordinator, +90 312 552 60 00

    Recruiting

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3107)

    Istanbul, 34722

    Study Coordinator, +902165666614

    Recruiting

  • Erciyes Universitesi Tıp Fakultesi Hastanesi ( Site 3111)

    Kayseri, 38039

    Study Coordinator, 905388731881

    Recruiting

  • Ondokuz Mayıs Universitesi ( Site 3112)

    Korfez Mahallesi, Samsun, 55270

    Study Coordinator, +903623121919

    Recruiting

Other trials in Turkey (Türkiye)

Argentina7 sites, 7 recruiting

  • Hospital Aleman-Oncology ( Site 0202)

    Buenos Aires, C1118AAT

    Study Coordinator, +541148277000

    Recruiting

  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0213)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1199ABB

    Study Coordinator, +541149590200

    Recruiting

  • Hospital Británico de Buenos Aires-Oncology ( Site 0207)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB

    Study Coordinator, +541143096400

    Recruiting

  • Hospital Privado Universitario de Córdoba-Hematology and Oncology ( Site 0204)

    Córdoba, X5016KEH

    Study Coordinator, +543514688200

    Recruiting

  • Sanatorio Británico-Clinical Oncology Department ( Site 0206)

    Rosario, Santa Fe Province, S2000CVB

    Study Coordinator, 5493416575134

    Recruiting

  • Sanatorio Parque ( Site 0205)

    Rosario, Santa Fe Province, S2000DSV

    Study Coordinator, 5493416955611

    Recruiting

  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 0217)

    San Miguel de Tucumán, Tucumán Province, T4000IHE

    Study Coordinator, 543814752113

    Recruiting

Other trials in Argentina

Brazil7 sites, 7 recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0304)

    Barretos, São Paulo, 14784400

    Study Coordinator, +551733216638 ex6638

    Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 0301)

    Natal, Rio Grande do Norte, 59062-000

    Study Coordinator, +558440095595

    Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0303)

    Porto Alegre, Rio Grande do Sul, 90020-090

    Study Coordinator, 51997292910

    Recruiting

  • Hospital Nossa Senhora da Conceição ( Site 0302)

    Porto Alegre, Rio Grande do Sul, 91350-200

    Study Coordinator, +555133572296

    Recruiting

  • Instituto de Oncologia Saint Gallen ( Site 0319)

    Santa Cruz do Sul, Rio Grande do Sul, 96830-180

    Study Coordinator, +55513056-8686

    Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0313)

    São José do Rio Preto, São Paulo, 15090-000

    Study Coordinator, +55 1798135-0180

    Recruiting

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 0305)

    São Paulo, 01246-000

    Study Coordinator, +551138932632

    Recruiting

Other trials in Brazil

South Korea7 sites, 7 recruiting

  • Chungbuk National University Hospital-Internal medicine ( Site 1000)

    Cheongju-si, North Chungcheong, 28644

    Study Coordinator, +82-43-269-6015

    Recruiting

  • Keimyung University Dongsan Hospital CRC room 1 ( Site 1006)

    Daegu, Taegu-Kwangyokshi, 42601

    Study Coordinator, +82532586671

    Recruiting

  • National Cancer Center-Lung Cancer Center ( Site 1002)

    Goyang-si, Kyonggi-do, 10408

    Study Coordinator, +82319201694

    Recruiting

  • Seoul National University Bundang Hospital-Medical Oncology ( Site 1003)

    Seongnam, Kyonggi-do, 13620

    Study Coordinator, +82-31-787-7071

    Recruiting

  • Asan Medical Center-Lung Cancer Center ( Site 1005)

    Seoul, 05505

    Study Coordinator, +82319201694

    Recruiting

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1004)

    Seoul, 06351

    Study Coordinator, 82-2-3410-3453

    Recruiting

  • The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 1001)

    Suwon, Kyonggi-do, 16247

    Study Coordinator, 82-31-249-8455

    Recruiting

Other trials in South Korea

Taiwan7 sites, 6 recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1103)

    Kaohsiung City, 807

    Study Coordinator, +88673121101

    Recruiting

  • Taichung Veterans General Hospital-Chest ( Site 1101)

    Taichung, 40705

    Study Coordinator, +886423592525x3256

    Recruiting

  • National Cheng Kung University Hospital-Clinical Trial Center ( Site 1102)

    Tainan, 704

    Completed

  • National Taiwan University Hospital-Oncology ( Site 1104)

    Taipei, 10002

    Study Coordinator, +886223123456x267511

    Recruiting

  • National Taiwan University Cancer Center (NTUCC) ( Site 1105)

    Taipei City, Taipei, 106

    Study Coordinator, +886223123456x271659

    Recruiting

  • Tri-Service General Hospital ( Site 1100)

    Taipei City, Taipei, 114

    Study Coordinator, +886287923311x13899

    Recruiting

  • Taoyuan General Hospital ( Site 1106)

    Taoyuan City, Taoyuan, 33004

    Study Coordinator, +88633699721x8502

    Recruiting

Other trials in Taiwan

Mexico6 sites, 6 recruiting

  • Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 0504)

    Chihuahua City, 31123

    Study Coordinator, +52 614 455 9270

    Recruiting

  • Mediadvance Clinical ( Site 0502)

    Chihuahua City, 31203

    Study Coordinator, +52 614 674 0705

    Recruiting

  • CIO - Centro de Inmuno-Oncología de Occidente ( Site 0506)

    Guadalajara, Jalisco, 44630

    Study Coordinator, +52 33 3044 7001

    Recruiting

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0508)

    Monterrey, Nuevo León, 64460

    Study Coordinator, 5519336943

    Recruiting

  • Centro de Investigacion Clinica de Oaxaca ( Site 0509)

    Oaxaca City, Oaxaca, 68020

    Study Coordinator, 951209524

    Recruiting

  • Oaxaca Site Management Organization S.C. ( Site 0507)

    Oaxaca City, 68000

    Study Coordinator, 529515147056

    Recruiting

Other trials in Mexico

Spain6 sites, 6 recruiting

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2900)

    Barcelona, 08035

    Study Coordinator, +34932746000

    Recruiting

  • Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2901)

    L'Hospitalet de Llobregat, Barcelona, 08908

    Study Coordinator, +34932607744

    Recruiting

  • Hospital Insular de Gran Canaria-Oncology ( Site 2903)

    Las Palmas de Gran Canaria, Las Palmas, 35016

    Study Coordinator, +34 928441738

    Recruiting

  • Hospital Clinico San Carlos-Oncology Department ( Site 2904)

    Madrid, 28040

    Study Coordinator, 34 913303000 x484835

    Recruiting

  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2902)

    Pozuelo de Alarcón, Madrid, 28223

    Study Coordinator, 34914521987

    Recruiting

  • CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 2905)

    Santiago de Compostela, La Coruna, 15706

    Study Coordinator, +34981950511

    Recruiting

Other trials in Spain

Chile5 sites, 5 recruiting

  • FALP-UIDO ( Site 0401)

    Providencia, Region M. de Santiago, 7500921

    Study Coordinator, +56224205098

    Recruiting

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0404)

    Santiago, Region M. de Santiago, 7500653

    Study Coordinator, +56991612199

    Recruiting

  • Clínica RedSalud Vitacura ( Site 0412)

    Santiago, Region M. de Santiago, 7650018

    Study Coordinator, +56 9 8292 6243

    Recruiting

  • Bradfordhill-Clinical Area ( Site 0400)

    Santiago, Region M. de Santiago, 8420383

    Study Coordinator, +56229490970

    Recruiting

  • ONCOCENTRO APYS-ACEREY ( Site 0410)

    Viña del Mar, Valparaiso, 2520598

    Study Coordinator, +56323320850

    Recruiting

Other trials in Chile

Peru5 sites, 5 recruiting

  • IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 0604)

    Lima, 15036

    Study Coordinator, +51 956 754 968

    Recruiting

  • Oncosalud ( Site 0602)

    Lima, 15036

    Study Coordinator, +51 988 966 244

    Recruiting

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 0600)

    Lima, 15038

    Study Coordinator, +51 957511783

    Recruiting

  • Instituto Neuro Cardiovascular de las Americas ( Site 0607)

    Lima, 15038

    Study Coordinator, +51 991366612

    Recruiting

  • Hospital Nacional Edgardo Rebagliati Martins-medical oncology ( Site 0603)

    Lima, Lima11

    Study Coordinator, +51998870468

    Recruiting

Other trials in Peru

United Kingdom5 sites, 5 recruiting

  • Addenbrooke's Hospital ( Site 3217)

    Cambridge, Cambridgeshire, CB2 2QQ

    Study Coordinator, +441223 805000

    Recruiting

  • St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3203)

    London, London, City of, EC1A 7BE

    Study Coordinator, 02073777000

    Recruiting

  • Freeman Hospital-Northern Centre for Cancer Care ( Site 3212)

    Newcastle upon Tyne, NE7 7DN

    Study Coordinator, 01912336161

    Recruiting

  • Mount Vernon Hospital ( Site 3218)

    Northwood, Hillingdon, HA6 2RN

    Study Coordinator, 02038262403

    Recruiting

  • Churchill Hospital ( Site 3219)

    Oxford, Oxfordshire, OX3 7LE

    Study Coordinator, +44 (0) 300 304 7777

    Recruiting

Other trials in United Kingdom

Austria4 sites, 4 recruiting

  • Medizinische Universitaet Innsbruck-Department for Internal Medicine V ( Site 1403)

    Innsbruck, Tyrol, 6020

    Study Coordinator, 43512 50480308

    Recruiting

  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 1402)

    Linz, Upper Austria, 4020

    Study Coordinator, 4373276764428

    Recruiting

  • Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 1401)

    Vienna, 1140

    Study Coordinator, 4319106042008

    Recruiting

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 1400)

    Vienna, 1210

    Study Coordinator, 431277002237

    Recruiting

Other trials in Austria

Canada4 sites, 4 recruiting

  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0100)

    Greenfield Park, Quebec, J4V 2H1

    Study Coordinator, 450-466-5000#3226

    Recruiting

  • Centre Hospitalier de l'Université de Montréal ( Site 0104)

    Montreal, Quebec, H2X 3E4

    Study Coordinator, 5148908000x26214

    Recruiting

  • St. Marys Hospital Center ( Site 0107)

    Montreal, Quebec, H3T 1M5

    Study Coordinator, 514-345-3511

    Recruiting

  • McGill University Health Centre ( Site 0105)

    Montreal, Quebec, H4A 3J1

    Study Coordinator, 5149341934X36675

    Recruiting

Other trials in Canada

Israel4 sites, 4 recruiting

  • Rambam Health Care Campus-Oncology Division ( Site 2203)

    Haifa, 3109601

    Study Coordinator, +972-4-7776234

    Recruiting

  • Shaare Zedek Medical Center ( Site 2206)

    Jerusalem, 9103102

    Study Coordinator, +97226555768

    Recruiting

  • Rabin Medical Center ( Site 2204)

    Petah Tikva, 4941492

    Study Coordinator, +97239378086

    Recruiting

  • Sheba Medical Center ( Site 2200)

    Ramat Gan, 5265601

    Study Coordinator, +972-35307032

    Recruiting

Other trials in Israel

Norway4 sites, 4 recruiting

  • Drammen Sykehus, Vestre Viken HF ( Site 2502)

    Drammen, Buskerud, 3004

    Study Coordinator, +4732803000

    Recruiting

  • Sykehuset Innlandet HF Gjøvik ( Site 2503)

    Gjøvik, Oppland, 2819

    Study Coordinator, +4791 50 62 00

    Recruiting

  • Akershus Universitetssykehus ( Site 2501)

    Lørenskog, Akershus, 1478

    Study Coordinator, +4767960000

    Recruiting

  • Oslo universitetssykehus HF. Radiumhospitalet ( Site 2504)

    Oslo, 0379

    Study Coordinator, +4722934000

    Recruiting

Other trials in Norway

Portugal4 sites, 4 recruiting

  • Instituto Portugês de Oncologia de Coimbra Francisco Gentil-Oncologia Médica ( Site 2704)

    Coimbra, 3000-075

    Study Coordinator, (351)217229800

    Recruiting

  • Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 2703)

    Lisbon, Lisbon District, 1769-001

    Study Coordinator, (351)217548085

    Recruiting

  • UNIDADE LOCAL DE SAUDE DE MATOSINHOS-Serviço de Oncologia ( Site 2705)

    Matosinhos Municipality, Porto District, 4464-513

    Study Coordinator, (351) 229391233

    Recruiting

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2702)

    Porto, 4200-072

    Study Coordinator, (351)225084000

    Recruiting

Other trials in Portugal

Switzerland4 sites, 4 recruiting

  • Kantonsspital Graubünden-Medizin ( Site 3006)

    Chur, Kanton Graubünden, 7000

    Study Coordinator, +41812566646

    Recruiting

  • HFR Fribourg - Hôpital Cantonal ( Site 3004)

    Fribourg, 1708

    Study Coordinator, +41263062015

    Recruiting

  • CHUV (centre hospitalier universitaire vaudois) ( Site 3003)

    Lausanne, Canton of Vaud, 1011

    Study Coordinator, +41795560440

    Recruiting

  • Kantonsspital Münsterlingen - Spital Thurgau AG ( Site 3005)

    Münsterlingen, Thurgau, 8596

    Study Coordinator, +41 58 144 1563

    Recruiting

Other trials in Switzerland

Australia3 sites, 3 recruiting

  • The Prince Charles Hospital ( Site 0700)

    Brisbane, Queensland, 4032

    Study Coordinator, +61736470368

    Recruiting

  • Fiona Stanley Hospital-Medical Oncology ( Site 0705)

    Murdoch, Western Australia, 6150

    Study Coordinator, 08 61526530

    Recruiting

  • Westmead Hospital ( Site 0701)

    Westmead, New South Wales, 2145

    Study Coordinator, 0298455200

    Recruiting

Other trials in Australia

Belgium3 sites, 3 recruiting

  • Antwerp University Hospital-Thoracic Oncology ( Site 1503)

    Edegem, Antwerpen, 2650

    Study Coordinator, +32 3 821 56 81

    Recruiting

  • VITAZ ( Site 1500)

    Sint-Niklaas, Oost-Vlaanderen, 9100

    Study Coordinator, +32 3760 2926

    Recruiting

  • Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 1502)

    Yvoir, Namur, 5530

    Study Coordinator, 081423351

    Recruiting

Other trials in Belgium

Hong Kong3 sites, 3 recruiting

  • Queen Mary Hospital ( Site 3400)

    Hksar

    Study Coordinator, +852 2255 3838

    Recruiting

  • Hong Kong United Oncology Centre ( Site 3403)

    Kowloon

    Study Coordinator, +852 2386 8002

    Recruiting

  • Queen Elizabeth Hospital ( Site 3402)

    Yau Ma Tei, 999077

    Study Coordinator, +852 3506 8888

    Recruiting

Other trials in Hong Kong

Czechia2 sites, 2 recruiting

  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 1600)

    Brno, Brno-mesto, 656 53

    Study Coordinator, +420543134008

    Recruiting

  • Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 1601)

    Ostrava, Ostrava Mesto, 703 00

    Study Coordinator, +420595633400

    Recruiting

Other trials in Czechia

New Zealand1 site, 1 recruiting

  • Auckland City Hospital ( Site 0800)

    Auckland, 1023

    Study Coordinator, +6493074949

    Recruiting

Other trials in New Zealand

About this study

Official title: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Being tested
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine
Keywords
Carcinoma, Lung cancer, Non-small cell lung cancer
Medical subject headings
Carcinoma, Non-Small-Cell Lung, Carcinoma, Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sacituzumab tirumotecanBiological

    Also called MK-2870, sac-TMT, SKB264

    Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 24 weeks

  • PembrolizumabBiological

    Also called MK-3475

    Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks

  • CisplatinDrug

    Cisplatin is administered as 75 mg/m^2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase

  • PemetrexedDrug

    Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m^2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.

  • GemcitabineDrug

    Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m^2 or 1250 mg/m^2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.

  • CarboplatinDrug

    Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.

  • PaclitaxelDrug

    Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m^2 or 200 mg/m^2 IV infusion q3w for up to 12 weeks as background treatment.

  • Rescue medicationDrug

    Participants are permitted to take rescue medications to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. Rescue medications include antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and granulocyte colony-stimulating factor. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.

Study groups in NCT06312137
Study groupRoleWhat they receive
Pembrolizumab + Sacituzumab tirumotecanExperimentalParticipants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by sacituzumab tirumotecan 4 mg/kg IV infusion every 2 weeks (Q2W) for up to 12 doses (~24 weeks) with pembrolizumab monotherapy 200 mg IV infusion every 6 weeks (Q6W) for up to 7 cycles (~42 weeks).
Receives: Biological: Sacituzumab tirumotecan; Biological: Pembrolizumab; Drug: Rescue medication
PembrolizumabActive comparatorParticipants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by pembrolizumab monotherapy 200 mg IV infusion Q6W for up to 7 cycles (~42 weeks).
Receives: Biological: Pembrolizumab; Drug: Cisplatin; Drug: Pemetrexed; Drug: Gemcitabine; Drug: Carboplatin; Drug: Paclitaxel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)

    DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first.

    Measured: Up to ~ 93 months

Secondary outcomes (12)

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Measured: Up to ~ 118 months

  2. Distant metastasis-free survival (DMFS) as assessed by investigator

    DMFS is defined as the time from randomization to the first documented distant metastasis or death due to any cause, whichever occurs first. Distant metastasis refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.

    Measured: Up to ~ 118 months

  3. Disease-Free Survival (DFS) as assessed by investigator

    DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first.

    Measured: Up to ~ 118 months

  4. Lung Cancer Specific Survival (LCSS)

    LCSS is defined as the time from randomization to the date of death due to lung cancer.

    Measured: Up to ~ 118 months

  5. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Measured: Up to ~ 118 months

  6. Number of Participants Who Discontinue Study Intervention Due to AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an AE will be presented.

    Measured: Up to ~ 118 months

  7. Change from Baseline in Global Health Status/Quality of Life (QoL) score (Quality of Life Questionnaire (QLQ)-C30 Items 29 and 30)

    The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is a psychometrically and clinically validated instrument appropriate for assessing the health-related quality of life (HRQoL) of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for the global health status or QoL a higher value indicates a better level of function.

    Measured: Baseline and up to ~118 months

  8. Change from Baseline in Physical Functioning Score (QLQ-C30 Items 1 to 5)

    The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for all physical functional scales, a higher value indicates a better level of function.

    Measured: Baseline and up to ~118 months

  9. Change from Baseline in Role Functioning Score (QLQ-C30 Items 6 and 7)

    The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for all role functional scales, a higher value indicates a better level of function.

    Measured: Baseline and up to ~118 months

  10. Change from Baseline in Dyspnea scores (QLQ-C30 Item 8)

    The EORTC-QLQ is a psychometrically and clinically validated instrument appropriate for assessing the HRQoL of cancer patients in oncology studies. Each scale or item is scored between 0 and 100, for symptom scales such as dyspnea, a higher value indicates increased severity of symptoms.

    Measured: Baseline and up to ~118 months

  11. Change from Baseline in Coughing scores (QLQ-LC24 Items 31 and 52)

    The lung cancer module of the EORTC, QLQ-LC24 is a revised and updated version of the Lung Cancer Module QLQ-LC13 and is a supplementary lung cancer specific module to be used along with EORTC QLQ C30. The QLQ-LC24 incorporates 4 multi-item scales to assess coughing, shortness of breath, hair problems, and fear of progression, for symptom scales as for cough, a higher value indicates increased severity of symptoms.

    Measured: Baseline and up to ~118 months

  12. Change from Baseline in Chest pain scores (QLQ-LC24 Item 40)

    The lung cancer module of the EORTC, QLQ-LC24 is a revised and updated version of the Lung Cancer Module QLQ-LC13 and is a supplementary lung cancer specific module to be used along with EORTC QLQ C30. The QLQ-LC24 incorporates 4 multi-item scales to assess coughing, shortness of breath, hair problems, and fear of progression, for symptom scales as for chest pain, a higher value indicates increased severity of symptoms.

    Measured: Baseline and up to ~118 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Mar 2024
  2. Study start3 Apr 2024
  3. Primary completion21 Feb 2034 (estimated)
  4. Study completion23 Oct 2034 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
This is a multi site study
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
780 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06312137
Sponsor's protocol ID
2870-019
Other IDs
2023-508012-35-00, MK-2870-019, jRCT2021240020, U1111-1297-4260, 2023
Acronym
TroFuse-019
Status last verified
Oct 2026
First submitted
8 Mar 2024
Last updated
15 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Sacituzumab tirumotecan, Pembrolizumab and Cisplatin in people with Non Small Cell Lung Cancer, run by Merck Sharp & Dohme LLC at 270 sites in 31 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 270 sites in United States, China, Japan, Italy, Germany and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Toll Free Number (1-888-577-8839, Trialsites@msd.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR) (time frame: Up to ~ 93 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06312137.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in